How it works:
Idelalisib selectively inhibits PI3K delta, a key enzyme in B-cell receptor signalling, disrupting tumour cell survival and proliferation. It is an oral targeted therapy, especially effective in patients who are refractory to previous lines of treatment or are unfit for standard chemotherapy.
Recommended for:
Patients with chronic lymphocytic leukaemia (CLL), especially fludarabine-refractory
Follicular lymphoma patients after at least two prior therapies
Patients with small lymphocytic lymphoma (SLL)
Individuals unsuitable for conventional chemotherapy
Patients requiring precision therapy
Chronic lymphocytic leukaemia (CLL)
Follicular lymphoma (FL)
Small lymphocytic lymphoma (SLL)
Take orally twice daily with 12-hour intervals. Swallow the tablet whole with water, with or without food. Treatment must be prescribed by a specialist and regularly monitored through liver function tests, blood counts, and symptom tracking.
Hypersensitivity to idelalisib or excipients
Severe hepatic impairment
Active viral infections (e.g., hepatitis B)
Pregnancy and breastfeeding
Active autoimmune intestinal diseases
Diarrhoea, colitis
Elevated liver enzymes
Respiratory infections
Leukopenia, neutropenia
Skin rashes
Fatigue, fever
Rare: interstitial lung disease
